IOL Chemicals Gets EDQM Nod for Antidiabetic API

IOL Chemicals & Pharmaceuticals Limited (IOLCP) is proud to announce an important milestone in their pharmaceutical division after being awarded a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines & Health Care (EDQM) for their active pharmaceutical ingredient (API), Sitagliptin Phosphate Monohydrate.

The certificate dated October 27, 2025, indicates that the European regulatory authorities recognize IOLCP’s Sitagliptin Phosphate Monohydrate as meeting the highest standards of quality, safety, and regulatory compliance. Achieving this momentous goal positions the company as a trustworthy API producer and stimulates them to find new business opportunities in the European pharmaceutical market.

Sitagliptin Phosphate Monohydrate is the main component of oral antidiabetic drugs that work by regulating high blood sugar levels in patients suffering from type 2 diabetes. By granting this approval, the EDQM demonstrates the confidence in IOLCP to be a leader in supply of pharmaceutical solutions of the highest standards and in strict compliance with regulations worldwide.

Also Read: Telangana Targets 1 Lakh Cr Life Sciences Investment by 2030

The corporate announcement was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and it was conveyed to the National Stock Exchange of India (NSE) as well as to BSE Limited.

With this endorsement, IOLCP is moving closer to its goal of not only increasing its worldwide presence in the API market but also becoming a leading player in diabetes management segment. The awarding of the certificate attests to the ongoing efforts at IOLCP to maintain the highest quality standards, comply with regulations, and innovate in pharmaceutical ‍production.